Merck Frosst files new drug application (NDA) for blood clot imaging agent:
This article was originally published in Clinica
Merck Frosst has filed a Canadian NDA for a thrombus imaging agent. The agent is based on a genetically engineered human antibody to fibrin developed by US-based BioTechnology General.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.